Abstract
Cannabis is the most prevalent illicit substance used among schizophrenia patients. The effects of cannabis are mediated through the endocannabinoid system, which is a major regulator of neurotransmission and may be disturbed in schizophrenia. Though cognitive impairment in schizophrenia is well established, the effects of cannabis on cognition in schizophrenia patients are still unclear. This paper reviews 19 studies that examine the cognitive effects of cannabis on schizophrenia by comparing cognitive functioning of cannabis-using and non-using schizophrenia patients across a vast range of domains (memory, attention and processing speed, executive functions, visuospatial, psychomotor and language). Of the studies included in the review, 11 reported better cognitive functions among cannabis-using schizophrenia patients compared to non-users, 5 found minimal or no difference between the groups and 3 found poorer cognitive functions among cannabis-using schizophrenia patients compared to non-users. The inconsistencies in the studies reviewed may stem from significant methodological variance between the studies regarding patient selection, adequate controls, cognitive measures used, measures of cannabis use, additional drugs used, and clinical aspects of schizophrenia. These methodological issues are discussed, as well as possible explanations for the results presented and suggestions for future research in this field.
Keywords: Schizophrenia, cannabis, tetrahydrocannabinol, neurocognitive, neuropsychological, endocannabinoid system, neurotransmission, cognitive functioning, domains, cognitive measures.
Current Pharmaceutical Design
Title:Neurocognitive Functioning and Cannabis Use in Schizophrenia
Volume: 18 Issue: 32
Author(s): Aviv Segev and Shaul Lev-Ran
Affiliation:
Keywords: Schizophrenia, cannabis, tetrahydrocannabinol, neurocognitive, neuropsychological, endocannabinoid system, neurotransmission, cognitive functioning, domains, cognitive measures.
Abstract: Cannabis is the most prevalent illicit substance used among schizophrenia patients. The effects of cannabis are mediated through the endocannabinoid system, which is a major regulator of neurotransmission and may be disturbed in schizophrenia. Though cognitive impairment in schizophrenia is well established, the effects of cannabis on cognition in schizophrenia patients are still unclear. This paper reviews 19 studies that examine the cognitive effects of cannabis on schizophrenia by comparing cognitive functioning of cannabis-using and non-using schizophrenia patients across a vast range of domains (memory, attention and processing speed, executive functions, visuospatial, psychomotor and language). Of the studies included in the review, 11 reported better cognitive functions among cannabis-using schizophrenia patients compared to non-users, 5 found minimal or no difference between the groups and 3 found poorer cognitive functions among cannabis-using schizophrenia patients compared to non-users. The inconsistencies in the studies reviewed may stem from significant methodological variance between the studies regarding patient selection, adequate controls, cognitive measures used, measures of cannabis use, additional drugs used, and clinical aspects of schizophrenia. These methodological issues are discussed, as well as possible explanations for the results presented and suggestions for future research in this field.
Export Options
About this article
Cite this article as:
Segev Aviv and Lev-Ran Shaul, Neurocognitive Functioning and Cannabis Use in Schizophrenia, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884799
DOI https://dx.doi.org/10.2174/138161212802884799 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Outcome of Newborns with Neonatal Seizures: Risk Factors and Predictors
Current Pediatric Reviews REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular
Current Neuropharmacology Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry Striatal-enriched Tyrosine Protein Phosphatase (STEP) in the Mechanisms of Depressive Disorders
Current Protein & Peptide Science Synthesis and Biological Evaluation of Novel 2,3-disubstituted Benzofuran Analogues of GABA as Neurotropic Agents
Medicinal Chemistry Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry A Review on Mechanistic and Pharmacological Findings of Diabetic Peripheral Neuropathy including Pharmacotherapy
Current Diabetes Reviews The Sense of Taste in the Upper Gastrointestinal Tract
Current Pharmaceutical Design Molecular Docking Study, Green Synthesis and Pharmacological Evaluation of 1,3,4-thiadiazole Derivatives as Potential Antiepileptic Agents
Mini-Reviews in Medicinal Chemistry Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Past, Present and Future of Antiepileptic Drug Therapy - Finding a Place for Heterocyclics
Mini-Reviews in Medicinal Chemistry Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Fluorescent Dyes for Bio-Applications in the Patent Literature
Recent Patents on Materials Science Pharmacological Management of Huntingtons Disease: An Evidence- Based Review
Current Pharmaceutical Design Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders
Current Medicinal Chemistry